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Introduction: A pilot trial was carried out to determine if a focussed narrative interview could alleviate
the components of suffering and anxiety and depression in advanced cancer patients.
Intervention: Patients recruited were invited to participate in a focussed narrative interview and reﬂect
on their perspectives on their sense of ‘‘meaning’’, regarding suffering and their psychological, physical,
social and spiritual well being – the emphasis was on allowing the patient to tell their story. Patients
were encouraged to share what resources they themselves had utilised in addition to what professional
care they may have received, to maintain a sense of well being.
Method: Patients with advanced metastatic disease were recruited from hospices in the North West of
England – the only exclusion criteria were not being able to understand written and spoken English and
a non cancer diagnosis. At recruitment patients were asked to complete a numerical scale for suffering;
the Brief Edinburgh Depression Scale, Edmonton Symptom Assessment Scale (ESAS), FACIT Spiritual
well being questionnaire, Demographic information was collected and patients were randomised to
either the intervention arm of the trial or the usual care arm of the study. Patients in both groups were
invited to complete each measure at 2, 4 and 8 weeks.
Results: One hundred people were recruited into the study – 49 were randomised to intervention group
and 51 to control group. The median age of patients was 66 years age range (31–89 years) and 68% of
patients were female. At baseline the ECOG performance of 75% of patients recruited was 1 or 2. The
median survival of all patients in the study was 169.5 days (range 10 days to still alive at end of study).
There was no signiﬁcant difference at any timepoint in scores on suffering measure between
intervention group and control group. At each time point the intervention demonstrated mean
improvement in scores for depression and anxiety on ESAS – the greatest changes for both depression
and anxiety were seen at 4 weeks.
Conclusion: This pilot randomised controlled trial of a focussed narrative intervention demonstrated an
improvement in mean changes in scores for depression and anxiety at 2, 4, and 8 weeks. We suggest
this intervention may have beneﬁcial effects on depression and anxiety, but a larger powered trial is
required to determine the full effects.
& 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Suffering in advanced cancer is complex (Kuuppelomaki and
Lauri, 1998; Daneault et al., 2004; George, 2009; Baines and
Norlander, 2000) however not universal. Wilson et al., (2007)
reported that nearly half of advanced cancer patients did not
consider themselves to be suffering and in moderate to extreme
levels of suffering, depression or anxiety disorder was a signiﬁ-
cant factor.s).
Y-NC-ND license.There has been much interest recently in delivering interven-
tions to alleviate suffering and emotional distress in patients with
advanced cancer. Dignity therapy has shown beneﬁt in terms of
an improvement in dignity and quality of life (Chochinov et al.,
2005, 2006) In the original study, Dignity therapy was found to
positively impact on depressive symptoms however a later study,
reported no differences for depression or spiritual well being
(Chochinov et al., 2011). A similar therapy – Supportive expres-
sive group therapy reduced new symptoms of depression (Kissane
et al., 2007) in advanced cancer.
An intervention which allows patients to focus on issues that
are concerning them and allowing time to reﬂect on resources
and support from professionals may be helpful. It has been found
that ‘‘narrative therapy’’ makes an important contribution to the
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Carlick and Biley 2004).
We report the ﬁndings of a pilot randomised controlled trial of
a focussed narrative intervention to alleviate suffering in patients
with advanced cancer.2. Patients and methods
The study was carried out in hospice day units in North West of
England. Recruitment into the study commenced on 1st November
2009 and ended December 20th 2010. All patients older than 18
years with a diagnosis of advanced progressive cancer and attending
Hospice day care services were invited to participate in the study.
The only speciﬁc exclusion criteria were severe cognitive impair-
ment or insufﬁcient understanding of the English language.3. Procedure
Eligible patients were informed of the study by letter. Patients
who agreed to be contacted by the researcher received detailed
information. One hundred and forty six patients were given informa-
tion and 100 patients participated – reasons for non participation are
included in the attached ﬂow chart. Patients recruited completed the
Numerical Visual analogue scale of suffering, the six item Brief
Edinburgh Depression Scale (BEDS), FACIT Spirituality questionnaire
and Edmonton Symptom Assessment Scale (ESAS). Patients were
allocated to intervention arm or usual care by means of randomly
allocated opaque envelopes opened in presence of the patient after
collection of baseline measures. All patients randomised to the usual
care were offered the intervention, out of trial after completing
8 week follow-up. Follow-up questionnaires were completed at 2
weeks, 4 and 8 weeks following the delivery of intervention and
following baseline data for usual care arm. Any patient found to have
high scores on any measures at any time points were referred onto
the hospice team and managed according to hospice practice. Full
ethical approval for the study was obtained (Reference 09/H1017/95).Table 1
Baseline scores for control and intervention groups.
Baseline measure Control Intervention MW-up
BEDS score median (IQrange) 6.0 (4.0–9.0) 6.0 (2.0–9.0) 0.62
ESAS scores:
Pain median (IQ range) 4.0 (1.0–6.25) 4.0 (1.0–6.5) 0.91
Tiredness median (IQ range) 5.0 (3.75–7.0) 7.0 (5.0–8.0) 0.03
Nausea median (IQ range) 1.5 (0–5.25) 1.0 (0–4.0) 0.95
Depression median (IQ range) 1.5 (0–5.0) 2.0 (0–5.5) 0.57
Anxiety median (IQ range) 3.0 (0–6.5) 4.0 (1.5–7.0) 0.24
Drowsiness median (IQ range) 3.0 (0–6.0) 5.0 (1.0–8.0) 0.07
Appetite median (IQ range) 4.0 (2.0–5.0) 5.0 (2.5–7.0) 0.09
Wellbeing median (IQ range) 4.0 (2.0–6.0) 5.0 (4.0–5.0) 0.414. Questionnaires
The Edmonton Symptom Assessment Scale (ESAS) was devel-
oped for symptom assessment of palliative care patients – in
addition to presence and severity of nine symptoms common in
cancer patients, there is also an opportunity to add an item and
‘‘will to live’’ was included (Bruera et al., 1991) – a cut off of 2 can
be used for screening anxiety and depression (Vignaroli et al.,
2006). The Functional Assessment of Chronic Illness Therapy-
Spiritual Well-Being (FACIT-Sp) comprises two subscales – mea-
suring a sense of meaning and peace and the role of spiritual
belief in illness. A total score for spiritual well-being is also
produced (Peterman et al., 2002). The Brief Edinburgh Scale
(Lloyd-Williams et al., 2007) for depression has been developed
and validated for use in palliative care patients. The 10 point
numerical suffering scale was devised and piloted within clinical
settings and found to have good face validity and reliability.
Performance status was assessed using ECOG performance status
(Oken et al., 1982) which is scored from 0 to 4 – a score of
0 indicating no dependence and 4 maximum dependence.Breathlessness median (IQ range) 3.5 (0–7.0) 4.0 (0–7.0) 0.66
Will to live median (IQ range) 8.5(7.0–10.0) 9.0(7.5–10.0) 0.28
FACIT score
Spiritual concerns score median
(IQ range)
32.0 (25–38) 32.0 (25.5–39) 0.42
VAS Suffering scale median
(IQ range)
5.0 (1.0–7.0) 4.0 (2.5–6.5) 0.855. Statistical analysis
Date was entered onto SPSS version 14. Descriptive statistics
were carried out at each time point. Inferential statistical tests were
applied to determine any between group or within group differencesat each time point. The usual care and the intervention and usual
care group were compared for both primary and secondary out-
comes at 2, 4 and 8 weeks for both groups. The two groups were
compared as regards baseline demographic information. Informa-
tion regarding attrition and date of death was collected6. The intervention
Patients were invited to participate in a focussed narrative
interview. The researcher prompted the patient to discuss perspec-
tives on their sense of ‘‘meaning’’, their psychological, physical,
social and spiritual well being and sense of suffering – the emphasis
was on allowing the patient to tell their story. Patients were
encouraged to share what they felt had been the main causative
factor for any suffering but also to share what resources they had
utilised to maintain a sense of well being. A random selection of
digital recordings were assessed to ensure consistency and rigour of
intervention during the trial. The intervention was conducted at
randomisation or if patients requested, a few days later.7. Results
One hundred people were recruited into the study – 49
randomised to intervention group and 51 to usual care. The
median age was 66 years age range (31–89 years) and 68% were
female. Breast cancer accounted for 33% of diagnosis; colorectal
cancer for 16%, Lung cancer 13%, prostate 7% and 30.6% of patients
had been diagnosed with cancer within last 12 months. (Tables
1–3) At baseline the ECOG performance was rated as One for 19%;
two for 56%; three for 23% and four for 2% and the median
survival of all patients was 169.5 days (range 10 days to still alive
at end of study). At baseline symptoms of tiredness, drowsiness
and appetite were all statistically signiﬁcantly worse in the
intervention group indicating those patients randomised to inter-
vention group were more unwell. Twenty ﬁve patients died
during the study period – 11 (21.5%) in the usual care group –
median survival in the control group was 99 days (range 36–352
days) and 5 patients (9.8%) died within 3 months of recruitment.
Fourteen (28.5%) patients died in the intervention group and 10
patients (20.4%) died within 3 months of recruitment – the
median survival in the intervention group was 58.5 days (range
10–262 days) – this was not statistically different (p¼0.17) to
that of the usual care group
Table 2
Baseline Demographics for intervention and control groups.
Control
group
Intervention
group
P
Characteristic (n¼51) (n¼49)
Age (mean) 64.1 65.8 0.54
Male gender (%) 35.3 28.6 0.47
Married/cohabiting (%) 58.8 51.0 0.43
White/white British (%) 98.0 95.9 0.38
Diagnosed in last 12 months (%) 39.2 30.6 0.58
Antidepressant in previous 2 weeks (%) 19.6 22.4 0.73
Depression or stress-related disorder before
cancer diagnosis (%)
31.4 36.7 0.54
Table 3
Site of primary cancer.
Control group Intervention group
Site (n¼51) (n¼49)
N (%) N (%)
Breast 11 (21.6) 12 (24.5)
Lung 6 (11.8) 5 (10.2)
Bowel 8 (15.7) 8 (16.3)
Brain 1 (2.0) 1 (2.0)
Cervix 0 1 (2.0)
Head/neck 2 (3.9) 2 (4.1)
Kidney 2 (3.9) 2 (4.1)
Liver 1 (2.0) 1 (2.0)
Lymphoma 3 (5.9) 5 (10.2)
Oesophageal 2 (3.9) 1 (2.0)
Ovarian 0 1 (2.0)
Myeloma 0 1 (2.0)
Melanoma 1 (2.0) 1 (2.0)
Pancreatic 4 (7.8) 1 (2.0)
Prostate 3 (5.9) 4 (8.2)
Stomach 1 (2.0) 2 (4.1)
Uterus 1 (2.0) 1 (2.0)
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completed 2 week follow-up; 57% 4 week follow-up and 56%
completed 8 week follow-up with 43% of patients completing all
four follow-up measures (see attached ﬂow chart Fig.1). At base-
line the VAS suffering score inter quartile range was 1–7 and the
median score for the VAS for intervention group was 4. As can be
seen from Table 4 there was no difference at any timepoint in VAS
scores between intervention group and control group.
At baseline the median score on the BEDS was 6 (indicating
probable depression) with an interquartile range of scores of 2–9.
At 4 weeks, a non signiﬁcant improvement in mean change of
0.2 in scores was observed in the intervention group, but this was
not continued at 8 weeks and no other changes were observed in
BEDS score over the time of the study. At each time point patients
undergoing the intervention demonstrated improvement in mean
changes in scores for depression and anxiety on ESAS – the
greatest changes for both depression and anxiety were seen at
4 weeks where there was a mean change improvement of 1.0 in
anxiety score and a mean change improvement on 0.8 in depres-
sion scores – whilst the mean change improvement in anxiety
score persisted at1.0 for anxiety, the mean change improvement
in depression score reduced to 0.18 for depression at 8 weeks.
Patients randomised to the intervention group demonstrated a
statistically signiﬁcant improvement in pain at 8 weeks (po0.01).8. Discussion
This pilot randomised controlled trial of a focussed narrative
intervention suggests a beneﬁcial effect in anxiety and depressionbut the intervention did not impact on the primary outcome of
global suffering scores as measured by a Visual Analogue Scale.
Patients were recruited into this study from hospices in the
North West of England and included patients of all ages and
diagnoses. Patients were in the end stages of their disease and
25% of patients died within the study period. It is also of note that
median survival in the usual care group was 99 days whereas the
median survival was 58.5 days (range 10–262 days) in the
intervention group – although not statistically different it
suggests intervention group were more unwell with greater
physical symptom burden than those patients randomised to
the usual care group (Selby et al., 2011).
Patients in the study did not experience high rates of suffering
and it may not have been possible to observe changes in VAS
scores at the three follow-up time points due to ﬂoor and ceiling
effects. There was a trend for suffering scores to reduce in both
groups during 8 week follow-up. In the UK Hospice day care offers
a range of services and interventions (mainly based around
creative and diversional activities) all centred on a holistic model
of care and it is possible that these interventions offered to all
patients in our study reduced suffering scores. The FACIT-Sp was
used to determine if the intervention would impact on spirituality
scores – there were no observable differences at any time point.
This is similar to Chochinov et al. (2011), where baseline FACIT-Sp
scores in their population were similar to those recorded in this
study and no changes in spirituality scores were seen.
This pilot trial suggests that the focussed narrative can
improve anxiety and depression scores as measured by the
Edmonton Symptom Assessment Scale and the Brief Edinburgh
Depression Scale. The ESAS is a numerical scale and previous
research has suggested a cut off threshold of 2 for Depression on
ESAS scale (Vignaroli et al., 2006; Bagha et al., 2012). For
depression the effect of the narrative intervention was greatest
at 4 weeks post intervention as measured by both the BEDS and
ESAS however for anxiety mean point improvement continued at
8 weeks post intervention. These results are encouraging as
patients in our study were clearly very unwell and close to the
end of life when interventions are more complex to deliver and
more difﬁcult to observe results. A trial of cognitive behaviour
therapy in patients with advanced cancer (Moorey et al., 2009)
found CBT lowered anxiety scores over time but had no effect on
depression scores. Our intervention which can be delivered by a
member of health care staff with training and supervision could
be cost-effective as beneﬁcial effects are seen at 4 weeks post
intervention. Additionally an unexpected ﬁnding was that
patients randomised to intervention arm reported a signiﬁcantly
improved pain score on ESAS at 8 weeks compared to usual care
which could be a correlate of patients in intervention group
experiencing an improvement in their anxiety and depression
scores (Laird et al., 2011).9. Strengths and limitations of the study
A key strength of this study is a randomised trial within a
hospice day care setting with patients of all ages and diagnostic
groups, and follow-up for 8 weeks. A number of validated tools
were used however these tools may not have been sensitive to
change and also the ﬂoor and ceiling effects observed. Addition-
ally we did not ‘‘screen out’’ patients with low levels of suffering.10. Conclusions
We believe that a simple focussed narrative intervention may
have a role in treatment of depression and anxiety which are both
Assessed for eligibility (146 patients)
Reasons for non participation included
1) Not feeling well enough
2) Already involved in clinical trial
3) Did not wish to participate in 8 week study 
Week 8  = 31 patients completed follow up
23 patients completed all follow -ups 
Week 2 = 39 completed follow up 
Week 4 = 34 patients completed follow up
51 patients 
Week 2 = 34 patients completed follow up
Week 4 = 23 patients completed follow up
49 patients
Week 8 = 25 patients completed follow -up
20 patients completed all follow -ups 
Allocation
Follow-Up
Follow-Up
Randomized 
Enrollment
Usual care Narrative
Intervention
Fig. 1. Flow chart.
Table 4
Median outcome scores for control and intervention groups at baseline, 2, 4 week and 8 week follow-up.
Baseline Intervention 2 week follow-up 4 week follow-up 8 week follow-up
Control Control Intervention Control Intervention Control Intervention
Baseline measure
BEDS score median 6.0 6.0 4.0 5.0 3.5 6.0 4.0 7.0
ESAS scores:
Pain median 4.0 4.0 4.0 4.0 4.0 3.0 2.0 4.0
Tiredness median 5.0 7.0 6.0 6.5 6.0 7.0 5.0 6.5
Nausea median 1.5 1.0 1.0 1.0 2.0 2.0 1.0 1.0
Depression median 1.5 2.0 1.0 2.5 1.0 2.0 1.0 2.0
Anxiety median 3.0 4.0 2.0 4.0 3.0 3.5 2.0 3.5
Drowsiness median 3.0 5.0 3.0 5.0 3.0 4.5 3.0 4.0
Appetite median 4.0 5.0 3.0 5.0 4.0 5.0 3.0 5.0
Wellbeing median 4.0 5.0 3.0 5.0 4.5 5.0 4.0 5.0
Breathlessness median 3.5 4.0 3.0 4.0 2.0 3.0 2.0 4.0
Will to live median 8.5 9.0 9.0 9.0 9.0 8.0 9.0 8.0
FACIT scores:
Spiritual well-being median 32.0 32.0 30.0 29.0 30.0 27.0 34.0 31.0
VAS Suffering scale median 5.0 4.0 3.0 3.0 3.5 3.0 3.0 3.0
No of patients 51 49 39 34 34 23 31 25
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would wish to replicate this intervention a larger trial prior to
supporting its widespread utilisation.
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